CTLA4 and lymphoma: In a cord blood-humanized mouse model, combining PD-1 and CTLA-4 blockade reduces the proliferation of lymphomas (induced by EVB), suggesting that PD-1/CTLA-4 blockade could serve as a candidate therapeutic target for EBV related complications [39].